Medassets Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Medassets Inc (MDAS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Medassets Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,275M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-17.8% annualized vs trailing 12 months).
- Peer revenue share: Medassets Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MDAS Sales vs. its Competitors, 2015
Medassets Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Software & Programming industry grew revenue 16.0% year over year, combined, vs 49.1% for Medassets Inc. Medassets Inc's share of combined industry revenue moved from 0.06% to 0.08%, a gain of 0.02 percentage points.
Medassets Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Medassets Inc | - | - | - | - |
| High-Confidence Competitors (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MDAS Stock Performance relative to its Competitors
MDAS Stock Performance relative to High-Confidence Competitors
Medassets Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ani Pharmaceuticals Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Medassets Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.